A phase II trial of the super-enhancer inhibitor Minnelide™ in advanced refractory adenosquamous carcinoma of the pancreas.
Nebojsa SkorupanMehwish I AhmadSeth M SteinbergJane B TrepelDerek CridebringHaiyong HanDaniel D Von HoffChristine AlewinePublished in: Future oncology (London, England) (2022)
Adenosquamous carcinoma of the pancreas (ASCP) is a very rare and highly aggressive variant of pancreatic ductal adenocarcinoma, accounting for 0.5-4% of all pancreatic cancer cases in the USA. Current data indicate that epigenetic changes and MYC overexpression lead to squamous transdifferentiation of pancreatic tumor cells and development of ASCP. Minnelide™, an oral anti-super-enhancer drug that inhibits MYC expression in preclinical models of ASCP, has demonstrated safety in a phase I study. We describe the design for a phase II, open-label, single-arm trial of Minnelide in patients with advanced refractory ASCP.
Keyphrases
- phase ii
- open label
- transcription factor
- phase iii
- clinical trial
- binding protein
- phase ii study
- study protocol
- placebo controlled
- poor prognosis
- dna methylation
- double blind
- cell proliferation
- high grade
- gene expression
- electronic health record
- artificial intelligence
- big data
- machine learning
- cell therapy
- bone marrow